The cost-effectiveness of returning incidental findings from next-generation genomic sequencing

This publication has 40 references indexed in Scilit:

• Paternalism and the ACMG recommendations on genomic incidental findings: patients seen but not heard
  Genetics in Medicine, 2013
• Who's on first in exome and whole genome sequencing? Is it the patient or the incidental findings?
  Molecular Genetics and Metabolism, 2013
• Cost-effectiveness of the 21-gene recurrence score assay in the context of multifactorial decision making to guide chemotherapy for early-stage breast cancer
  Genetics in Medicine, 2013
• Influence of Patient Preferences on the Cost-Effectiveness of Screening for Lynch Syndrome
  Journal of Oncology Practice, 2012
• Future Directions in Malignant Hyperthermia Research and Patient Care
  Anesthesia & Analgesia, 2011
• Cost-Effectiveness of Genetic Testing in Family Members of Patients With Long-QT Syndrome
  Circulation: Cardiovascular Quality and Outcomes, 2011
• Good Research Practices for Measuring Drug Costs in Cost-Effectiveness Analyses: A Societal Perspective: The ISPOR Drug Cost Task Force Report—Part II
  Value in Health, 2010
• Efficacy of Antiarrhythmic Drugs in Arrhythmogenic Right Ventricular Cardiomyopathy
  JACC, 2009
• Variation of Breast Cancer Risk Among BRCA1/2 Carriers
  JAMA, 2008
• Managing Incidental Findings in Human Subjects Research: Analysis and Recommendations
  Journal of Law, Medicine & Ethics, 2008